Bayer Nexavar Safety Profile Fuels Research In Multiple Cancer Indications

A dual mode of action and favorable safety profile will be the chief selling points for Bayer/Onyx' kidney cancer agent Nexavar (sorafenib), company officials said during Bayer's R&D investor conference in London Dec. 8